Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic Buys Bladder-Control Neurostimulation Firm

This article was originally published in The Gray Sheet

Executive Summary

Medtronic plans to launch Advanced Uro-Solutions’ 510(k)-cleared Nuro percutaneous tibial nerve stimulation system in the next year following its Feb. 23 acquisition of the firm.

You may also be interested in...



Neuromodulation Devices Stimulate Opportunities In Urology

Neuromodulation for urological indications, notably overactive bladder (OAB), has been dominated since the late 1990s by Medtronic’s sacral-nerve stimulation system InterStim, with the more recent addition of Cogentix Medical’s Urgent PC for tibial nerve stimulation. Yet only a fraction of OAB patients receive effective neuromodulation treatment, and several companies hope to lower barriers to this modality by developing alternative devices for urological indications.

US Neurostimulation Devices Market Forecast to Grow By $1B+ With New Indications, New Technologies

The US neurostimulation technology market will grow nearly 46% over the next five years, according to a new report from Medtech Insight.

Boston Sci Ups Urology Focus With $1.6 Billion AMS Deal

The firm is expanding its leadership position in the urology space with its acquisition of American Medical Systems's men's health and prostate health units.

Related Content

Related Companies

Latest News
UsernamePublicRestriction

Register

MT034549

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel